FDA-Approved MedicationUpdated November 2026

Foundayo Guide

Foundayo (orforglipron) was the first small-molecule GLP-1 receptor agonist to win FDA approval in an oral once-daily form for chronic weight management. That approval landed on April 1, 2026. One tablet a day, with or without food, marking a major change from injectable GLP-1s and from oral semaglutide (Rybelsus), which has strict food and water rules. In the 72-week ATTAIN-1 phase 3 trial, the highest dose produced 11.1% mean weight loss versus 2.1% on placebo (FDA label, all randomized patients).

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

At a Glance

Foundayo at a glance
Generic NameOrforglipron
Brand NamesFoundayo
FDA StatusFDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Cannot be used with other GLP-1 receptor agonists.[1]
Approval DateApril 1, 2026[1]

How does Foundayo work?

Orforglipron is not built as a peptide. It is a small organic molecule that binds the GLP-1 receptor and switches it on directly. Unlike injectable GLP-1 peptides (semaglutide, tirzepatide) or oral peptide formulations (Rybelsus and Ozempic tablets), orforglipron is a true small organic molecule that survives stomach acid and digestion, eliminating the need for injection or special food restrictions. It produces the same downstream effects as injectable GLP-1 agonists: appetite suppression, slowed gastric emptying, and reduced food reward signaling.[2]

Dosing Schedule

Foundayo uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Days 1–300.8 mg orally once daily (starting dose)
Days 31–602.5 mg once daily
Day 61+5.5 mg once daily
Optional, every 30+ days9 mg, then 14.5 mg, then 17.2 mg once daily (maximum), based on response and tolerability

What side effects does Foundayo cause?

Common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, hair loss. Serious: pancreatitis, dehydration leading to kidney problems, gallbladder disease, hypoglycemia (especially with insulin/sulfonylureas), serious allergic reactions, diabetic retinopathy progression in T2D patients, increased aspiration risk during anesthesia. Boxed warning: risk of thyroid C-cell tumors. Other GLP-1 drugs caused these tumors in rats and mice; orforglipron is not active in rodents and did not produce them, and whether the finding applies to humans has not been determined. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]

Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].

Clinical Trial Results

ATTAIN-1 (NCT05869903; Wharton et al. NEJM 2025, PMID 40960239) ran 72 weeks at sites in 10 countries: phase 3, randomized, placebo-controlled, 3,127 adults, all of them obese or overweight carrying a weight-related comorbidity, none of them diabetic. The highest dose produced 11.1% mean body weight reduction (~25 lbs) versus 2.1% on placebo in all randomized patients (FDA label; the paper reports 11.2%). The trial dosed an investigational formulation at 6, 12 and 36 mg; the label converts these to the marketed 5.5, 9 and 17.2 mg tablets. Improvements were seen in waist size, systolic blood pressure, triglycerides and non-HDL cholesterol. ATTAIN-2 (NCT05872620; Horn et al. Lancet 2026, PMID 41275875), in 1,613 adults with type 2 diabetes, is complete: the highest dose cut body weight 9.6% versus 2.5% on placebo at 72 weeks.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where can you get Foundayo?

Sellers in our register that will dispense orforglipron, or a compounded version of it, after an online consultation — shipped to your door.

8.1/ 10
Verified partner

Sesame Care

Best for: oral orforglipron alongside the injectables

★★★★☆8.1/10

Editorial score · methodology

$149/mo+ care fee
BrandOrforglipron
Get StartedRead full Sesame Care review →
7.9/ 10
Verified partner

ShedRx

Best for: oral orforglipron alongside the injectables

★★★★☆7.9/10

Editorial score · methodology

$149/mo+ membership
BrandOrforglipronGHK-CuGlutathioneNAD+
Get StartedRead full ShedRx review →
7.3/ 10
Verified partner

Found

Best for: people who want clinician visits billed to commercial insurance, with compounded medication in the plan price

★★★★☆7.3/10

Editorial score · methodology

$149/mo+ membership
BrandOrforglipron
Get StartedRead full Found review →
6.3/ 10
Verified partner

SkinnyRx

Best for: starting below a standard dose, with microdose tiers

★★★☆☆6.3/10

Editorial score · methodology

$248/mo
BrandOrforglipron
Get StartedRead full SkinnyRx review →
9.1/ 10

LillyDirect

Best for: brand-name Zepbound or Foundayo bought from the manufacturer at a posted cash price

★★★★★9.1/10

Editorial score · methodology

$149/mo
BrandOrforglipron
Get StartedRead full LillyDirect review →
9.1/ 10

PreventiveMD

Best for: oral orforglipron alongside the injectables

★★★★★9.1/10

Editorial score · methodology

$149/mo
BrandOrforglipronGHK-CuGlutathioneNAD+LegitScript Verified
Get StartedRead full PreventiveMD review →

27 sellers in the register publish a price; the lowest starts at $149 a month, checked November 2026. What each one charges to start, cheapest at the top. Compounded orforglipron from state-licensed 503A pharmacies is legal under federal compounding law when made for an individual patient[3], and the rules loosen further, to include bulk compounding by 503B outsourcing facilities, only while a molecule sits on the FDA Drug Shortage List[4]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[5]. What you actually pay moves with your dose and with whatever promotion happens to be running.

Starting Foundayo price per seller, cheapest first. Prices in USD per month; checked November 2026.
ProviderStarting PriceLink
Amazon One Medical$149/mo + visit feeVisit
Found$149/mo + membershipVisit
GoodRx$149/moVisit
Healthspan$149/mo + membershipVisit
Hims$149/mo + membershipVisit
Imbue Health$149/mo + membershipVisit
Intermountain Health On-Demand Weight Loss$149/mo + consult feeVisit
Knownwell$149/mo + visit feeVisit
LillyDirect$149/moVisit
médetone$149/mo + membershipVisit
Show all 27 Foundayo sellers
Foundayo sellers 11 to 27, cheapest first. Prices in USD per month.
Mochi Health$149/mo + membershipVisit
PreventiveMD$149/moVisit
Ro$149/mo + membershipVisit
Sculpt Rx$149/mo + membershipVisit
Sesame Care$149/mo + care feeVisit
ShedRx$149/mo + membershipVisit
Walgreens Weight Management$149/mo + visit feeVisit
WeightWatchers Clinic$149/mo + membershipVisit
ZipHealth$149/mo + feesVisit
Maximus$199.99/moVisit
Alloy$248/moVisit
Phoenix NP$248/moVisit
SkinnyRx$248/moVisit
CLYR Health$329/moVisit
Näky$424/mo + membershipVisit
Pallas Health$499/moVisit
Immortals$750/mo, prepaidVisit

Short verdict pages setting Foundayo against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.

See all drug-vs-drug verdicts.

Questions people actually asked about Foundayo in named subreddits, each answered from the published trial data.

One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.

Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.

Foundayo (Orforglipron): the GLP-1 Pill With No Fasting Rule
Approved April 1, 2026, as the second GLP-1 tablet for weight management, and the only one taken with or without food. It produced 11.1% weight loss at 72 weeks, below both injectable rivals. The label, the trials and the interactions.
9 min read11 citations
Appetite Suppressants: Every FDA-Approved Drug and What Its Label Shows
The strongest appetite suppressants are prescription GLP-1 drugs: Zepbound beat placebo by 17.8 points of body weight on its label. Old stimulants like phentermine are approved for weeks. No OTC appetite suppressant is FDA-approved, and diet supplements keep hiding drugs.
11 min read27 citations
Foundayo (Orforglipron) Side Effects: Rates by Dose, Dropouts and Interactions
Foundayo's side effects are mostly digestive and rise with dose: nausea in 26% to 35% vs 10% on placebo, and 10% quit at the top dose. The FDA label's full table, when effects ease, serious risks, CYP3A4 interactions, and how it compares with the Wegovy pill and injections.
11 min read13 citations
Which Drugs Are GLP-1s? Mounjaro, Trulicity, Phentermine and 25 More, Checked
Ozempic, Wegovy, Rybelsus, Trulicity and Foundayo are GLP-1 receptor agonists; Mounjaro and Zepbound add GIP. Phentermine, Contrave, metformin, Jardiance, Januvia and insulin are not. 28 drugs sorted by what each FDA label calls them.
10 min read33 citations
How Long Do Zepbound, Wegovy and Other GLP-1s Stay in Your System?
Half-lives and washout times for tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), liraglutide, dulaglutide, orforglipron and investigational retatrutide, from FDA labels and trial data, with what the labels say about stopping before pregnancy or surgery.
7 min read9 citations
Does Mississippi Medicaid Cover Wegovy and Zepbound? Coverage, Criteria and Who Stays On
Mississippi Medicaid has paid for weight-loss drugs since July 2023 and updated its criteria on July 1, 2026. Which drugs are preferred, the BMI lines, renewal rules, how to file with Gainwell, and a study showing a quarter of adult starters still adherent at a year.
8 min read16 citations

Frequently Asked Questions

FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Cannot be used with other GLP-1 receptor agonists.
What you pay for Foundayo turns on who is selling it and in what form. Uninsured, the branded product runs roughly $1,000 to $1,600 a month; compounded versions through telehealth sellers usually land between $129 and $400. The table above carries the current figures from our register. Before you commit, check whether a manufacturer savings program applies to you.
Common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, hair loss. Serious: pancreatitis, dehydration leading to kidney problems, gallbladder disease, hypoglycemia (especially with insulin/sulfonylureas), serious allergic reactions, diabetic retinopathy progression in T2D patients, increased aspiration risk during anesthesia. Boxed warning: risk of thyroid C-cell tumors. Other GLP-1 drugs caused these tumors in rats and mice; orforglipron is not active in rodents and did not produce them, and whether the finding applies to humans has not been determined. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Foundayo is prescription-only, so someone licensed has to write it — your own doctor, an endocrinologist, or one of the telehealth sellers above. For compounded versions the telehealth route is usually both quicker and cheaper out of pocket than a traditional pharmacy.
Sources & methodology — as of November 2026
  1. 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  3. 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  4. 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  5. 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary

The words sellers use, defined. Tap any term.